Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Journal article
Mayne K. et al, (2024), Nephrology Dialysis Transplantation
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
Journal article
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol
Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
Journal article
Pessoa-Amorim G. et al, (2024), Trials, 25
EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY
Journal article
HERRINGTON W., (2024), Clinical and Experimental Nephrology
Mechanisms of rosuvastatin-related acute kidney injury following cardiac surgery: the STICS trial.
Journal article
Wijesurendra RS. et al, (2024), Eur Heart J, 45, 629 - 631
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None. et al, (2024), Nat Commun, 15
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Journal article
EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60
Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease
Journal article
Mayne K. et al, (2023), Journal of the American Society of Nephrology
Methylprednisolone, intravenous immunoglobulin, tocilizimab or anakinra for children with Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS CoV-2 (PIMS-TS, MIS-C) – report from a randomised, controlled, open-label, platform trial
Journal article
LANDRAY M. et al, (2023), Lancet Child and Adolescent Health
Delivering trials in the NHS: more than worth it.
Journal article
Haynes R. et al, (2023), Clin Med (Lond), 23, 525 - 526
Accelerating clinical trials: time to turn words into action.
Other
Landray MJ. et al, (2023), Lancet, 402, 165 - 168
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
Journal article
HERRINGTON W. et al, (2023), Kidney International Reports
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Preprint
Horby PW. et al, (2023)
Sacubitril/valsartan in Peritoneal Dialysis – Lessons from a Pharmacokinetic Study
Report
Judge P., (2023)
Randomised controlled trials for mpox in endemic countries.
Journal article
Rojek A. et al, (2023), Lancet Infect Dis
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: A Mendelian Randomization Study.
Journal article
Donovan K. et al, (2023), Clin J Am Soc Nephrol, 18, 17 - 27